Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study


Here are the Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Prevalence of kidney disease in patients meaning, prevalence of kidney stones in the us, prevalence of kidney disease in patients with cirrhosis, prevalence of kidney disease in saudi arabia, prevalence of kidney disease in patients experience.

Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study

Purpose: This study investigated the prevalence and risk factors of acute kidney injury (AKI) and chronic kidney disease (CKD) in cancer patients with the aim of providing guidance for clinical treatment of cancer patients.

Methods: A retrospective study was conducted on all cancer and hematological malignancy patients admitted to Xuanwu Hospital, Capital Medical University, from January 2018 to July 2023. The study population included patients aged 18–80 years with a confirmed cancer or malignancy diagnosis. Chi-square tests, Spearman's correlation, and logistic regression were used to evaluate the relationships between demographic factors, comorbidities, cancer types, antitumor drugs and the prevalence of AKI/CKD.

Results: Among the 2438 participants, the prevalence rates of AKI and CKD were 3.69% and 7.88%, respectively. Patients with diabetes had higher prevalence of AKI/CKD than those without diabetes (OR = 1.66, 95% C I 1.01–2.68, p = 0.040; OR = 1.60, 95% CI 1.10–2.31, p = 0.012, respectively). In addition, a higher prevalence of CKD was observed in patients with hypertension (OR = 3.49, 95% CI 2.43–5.06, p < 0.001). Underweight patients were more likely to develop AKI (OR = 2.66, 95% CI 1.03–6.08, p = 0.029). Anthracyclines may contribute to a higher risk of AKI, and antimetabolites and immunomodulators may be associated with the development of CKD. Overall, patients with hematological malignancies had significantly higher rates of AKI/CKD than those with solid tumors. Among solid tumor patients, the prevalence of AKI/CKD was low in patients with lung and breast cancer. Conclusions: AKI and CKD prevalence varies across cancer types, influenced by factors, such as diabetes, hypertension, body weight, and antitumor drugs. Tailored treatment plans are essential for improving cancer patient outcomes. © The Author(s), under exclusive licence to Springer Nature B.V. 2024.

Authors : Wu F.; Wang S.; Zhang J.; Wang P.; Zhang A.

Source : Springer Science and Business Media B.V.

Article Information

Year 2024
Type Article
DOI 10.1007/s11255-024-04130-5
ISSN 03011623
Volume 56

You can download the article here


If You have any problem, contact us here


Support Us:

Download Now Buy me a coffee Request Paper Here